NHS Facing Criticism Over Limited Tirzepatide Supply Amidst Obesity Crisis
The NHS is facing criticism for not providing enough tirzepatide, marketed as Mounjaro, to tackle the growing obesity crisis in the UK. With 64% of adults classified as overweight or obese, the high cost of the drug on the stock market today and black market is raising concerns.
Mounjaro, a once-weekly injection, has shown promising results in weight loss. A study found it can reduce an obese person's bodyweight by an average of 20% over 72 weeks. However, its high price point, £335 for a month's supply at Boots, has led many to seek alternatives.
The black market has emerged as a solution for some, with a month's supply ranging from £20 to £30, and bulk purchases potentially costing as little as £1.50. Two main groups are using these illegal sources: bodybuilders and others seeking cheaper options. An unknown but growing number are also risking fake GLP-1s.
Experts warn of a rapidly growing group of chronic kidney disease (CKD) patients with diabetes among GLP-1 drug users. This growth is influenced by new therapeutic evidence and recommendations for using GLP-1 receptor agonists in this high-risk patient group.
Hannah, who initially had reservations, started taking tirzepatide and lost half a stone in a month, highlighting its potential benefits. About 1.4 million people in the UK are currently sourcing tirzepatide and semaglutide through online pharmacies each month.
The high demand and limited NHS supply of Mounjaro have led to a thriving black market, raising concerns about affordability, accessibility, and safety. As the obesity crisis continues, addressing these issues will be crucial for ensuring equitable access to effective weight loss treatments.
